Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by gbengaon Dec 27, 2019 7:00pm

325 Views

Post# 30495721

RE:Is this the prelude to a buyout?

Another theory I heard is a MAJOR partnership with huge capital backing and more ... DYODD I am just another conspiracy theorist with an ear to the ground and some $47K locked in this baby for over four years now ... through thick and thin, sick and sin, those who believe will hold .... and be rewarded exceedingly well.

Bullboard Posts

The top 5 Canadian small-cap AI stocks